Uterine sarcoma Part II—Uterine endometrial stromal sarcoma: The TAG systematic review

Huann Cheng Horng; Kuo Chang Wen; Peng Hui Wang; Yi Jen Chen; Ming Shyen Yen; Heung Tat Ng; Yen Hou Chang; Yi Chang; Hsiang Tai Chao; Kuan Chong Chao; Chi Mu Chuang; Chi Hong Ho; Chen Yu Huang; Zhi Chen Hung; Ling Yu Jiang; Hei Yu Lau; Hsin Yang Li; Chi Yao Lin; Chia Hao Liu; Pi Lin Sun; Nae Fang Twu; Hua Hsi Wu; Hann Chin Yu; Fong Yuan Ju; Chih Ping Tsai; Wen Hsun Chang; Yen Mei Hsu; Na Rong Lee; Chih Yao Chen; Ting Chen Chang; Wen Chun Chang; Chii Hou Chen; Ruey Jian Chen; Song Nan Chow; Yih Ron Lien; Bor Ching Sheu; Pao Ling Torng; Men Luh Yen; Wen Ling Lee; Kuan Chin Wang; Chih Long Chang; Chih Ping Chen; Jen Ruei Chen; Tze Chien Chen; Jian Pei Huang; Ming Chao Huang; Yeou Lih Wang; Cheng Chang Chang; Jah Yao Liu; Her Young Su; Yu Chi Wang; Mu Hsien Yu; Lee Wen Huang; Kok Min Seow; Tsung Hsuan Lai; Fa Kung Lee; Ching Hui Chen; Ben Shian Huang; Sheng Mou Hsiao; Hsu Dong Sun; Wen Yih Wu; Sen Wen Teng; Kuo Hu Chen; Jeng Hsiu Hung; Hung Cheng Lai; Chiou Chung Yuan; Ching Hung Hsieh; Chin Jung Wang; Shing Jyh Chang; Man Jung Hung; Shih Tien Hsu; Yu Min Ke; Chien Hsing Lu; Lou Sun; Wei Chun Chang; Yao Ching Hung; Wu Chou Lin; Po Hui Wang; Tze Ho Chen; Yiu Tai Li; Meng Hsing Wu; Kuo Feng Huang; Hung Chun Fu; San Nung Chen; An Jen Chiang; Ju Yueh Li; Li Te Lin; Hsiao Wen Tsai; Kuan Hao Tsui

doi:10.1016/j.tjog.2016.04.034

Uterine sarcoma Part II—Uterine endometrial stromal sarcoma: The TAG systematic review

Huann Cheng Horng, Kuo Chang Wen, Peng Hui Wang^*, Yi Jen Chen, Ming Shyen Yen, Heung Tat Ng, Yen Hou Chang, Yi Chang, Hsiang Tai Chao, Kuan Chong Chao, Chi Mu Chuang, Chi Hong Ho, Chen Yu Huang, Zhi Chen Hung, Ling Yu Jiang, Hei Yu Lau, Hsin Yang Li, Chi Yao Lin, Chia Hao Liu, Pi Lin SunNae Fang Twu, Hua Hsi Wu, Hann Chin Yu, Fong Yuan Ju, Chih Ping Tsai, Wen Hsun Chang, Yen Mei Hsu, Na Rong Lee, Chih Yao Chen, Ting Chen Chang, Wen Chun Chang, Chii Hou Chen, Ruey Jian Chen, Song Nan Chow, Yih Ron Lien, Bor Ching Sheu, Pao Ling Torng, Men Luh Yen, Wen Ling Lee, Kuan Chin Wang, Chih Long Chang, Chih Ping Chen, Jen Ruei Chen, Tze Chien Chen, Jian Pei Huang, Ming Chao Huang, Yeou Lih Wang, Cheng Chang Chang, Jah Yao Liu, Her Young Su, Yu Chi Wang, Mu Hsien Yu, Lee Wen Huang, Kok Min Seow, Tsung Hsuan Lai, Fa Kung Lee, Ching Hui Chen, Ben Shian Huang, Sheng Mou Hsiao, Hsu Dong Sun, Wen Yih Wu, Sen Wen Teng, Kuo Hu Chen, Jeng Hsiu Hung, Hung Cheng Lai, Chiou Chung Yuan, Ching Hung Hsieh, Chin Jung Wang, Shing Jyh Chang, Man Jung Hung, Shih Tien Hsu, Yu Min Ke, Chien Hsing Lu, Lou Sun, Wei Chun Chang, Yao Ching Hung, Wu Chou Lin, Po Hui Wang, Tze Ho Chen, Yiu Tai Li, Meng Hsing Wu, Kuo Feng Huang, Hung Chun Fu, San Nung Chen, An Jen Chiang, Ju Yueh Li, Li Te Lin, Hsiao Wen Tsai, Kuan Hao Tsui

^*此作品的通信作者

醫學系婦產學科

研究成果: Review article › 同行評審

38 引文斯高帕斯（Scopus）

摘要

Endometrial stromal tumors are rare uterine tumors (<1%). Four main categories include endometrial stromal nodule, low-grade endometrial stromal sarcoma (LG-ESS), high-grade endometrial stromal sarcoma (HG-ESS), and uterine undifferentiated sarcoma (UUS). This review is a series of articles discussing the uterine sarcomas. LG-ESS, a hormone-dependent tumor harboring chromosomal rearrangement, is an indolent tumor with a favorable prognosis, but characterized by late recurrences even in patients with Stage I disease, suggesting the requirement of a long-term follow-up. Patients with HG-ESS, based on the identification of YWHAE-NUTM2A/B (YWHAE-FAM22A/B) gene fusion, typically present with advanced stage diseases and frequently have recurrences, usually within a few years after initial surgery. UUS is, a high-grade sarcoma, extremely rare, lacking a specific line of differentiation, which is a diagnosis of exclusion (the wastebasket category, which fails to fulfill the morphological and immunohistochemical criteria of translocation-positive ESS). Surgery is the main strategy in the management of uterine sarcoma. Due to rarity, complex biological characteristics, and unknown etiology and risk factors of uterine sarcomas, the role of adjuvant therapy is not clear. Only LG-ESS might respond to progestins or aromatase inhibitors.

原文	English
頁（從 - 到）	472-479
頁數	8
期刊	Taiwanese Journal of Obstetrics and Gynecology
卷	55
發行號	4
DOIs	https://doi.org/10.1016/j.tjog.2016.04.034
出版狀態	Published - 1 8月 2016

存取文件

10.1016/j.tjog.2016.04.034

其它文件與鏈接

Link to publication in Scopus

引用此

Horng, H. C., Wen, K. C., Wang, P. H., Chen, Y. J., Yen, M. S., Ng, H. T., Chang, Y. H., Chang, Y., Chao, H. T., Chao, K. C., Chuang, C. M., Ho, C. H., Huang, C. Y., Hung, Z. C., Jiang, L. Y., Lau, H. Y., Li, H. Y., Lin, C. Y., Liu, C. H., ... Tsui, K. H. (2016). Uterine sarcoma Part II—Uterine endometrial stromal sarcoma: The TAG systematic review. Taiwanese Journal of Obstetrics and Gynecology, 55(4), 472-479. https://doi.org/10.1016/j.tjog.2016.04.034

@article{b5abb290253b4c799d02f47eacf7df59,

title = "Uterine sarcoma Part II—Uterine endometrial stromal sarcoma: The TAG systematic review",

abstract = "Endometrial stromal tumors are rare uterine tumors (<1%). Four main categories include endometrial stromal nodule, low-grade endometrial stromal sarcoma (LG-ESS), high-grade endometrial stromal sarcoma (HG-ESS), and uterine undifferentiated sarcoma (UUS). This review is a series of articles discussing the uterine sarcomas. LG-ESS, a hormone-dependent tumor harboring chromosomal rearrangement, is an indolent tumor with a favorable prognosis, but characterized by late recurrences even in patients with Stage I disease, suggesting the requirement of a long-term follow-up. Patients with HG-ESS, based on the identification of YWHAE-NUTM2A/B (YWHAE-FAM22A/B) gene fusion, typically present with advanced stage diseases and frequently have recurrences, usually within a few years after initial surgery. UUS is, a high-grade sarcoma, extremely rare, lacking a specific line of differentiation, which is a diagnosis of exclusion (the wastebasket category, which fails to fulfill the morphological and immunohistochemical criteria of translocation-positive ESS). Surgery is the main strategy in the management of uterine sarcoma. Due to rarity, complex biological characteristics, and unknown etiology and risk factors of uterine sarcomas, the role of adjuvant therapy is not clear. Only LG-ESS might respond to progestins or aromatase inhibitors.",

keywords = "diagnosis, endometrial stromal sarcoma, treatment, undifferentiated sarcoma, uterine sarcoma, uterus",

author = "Horng, {Huann Cheng} and Wen, {Kuo Chang} and Wang, {Peng Hui} and Chen, {Yi Jen} and Yen, {Ming Shyen} and Ng, {Heung Tat} and Chang, {Yen Hou} and Yi Chang and Chao, {Hsiang Tai} and Chao, {Kuan Chong} and Chuang, {Chi Mu} and Ho, {Chi Hong} and Huang, {Chen Yu} and Hung, {Zhi Chen} and Jiang, {Ling Yu} and Lau, {Hei Yu} and Li, {Hsin Yang} and Lin, {Chi Yao} and Liu, {Chia Hao} and Sun, {Pi Lin} and Twu, {Nae Fang} and Wu, {Hua Hsi} and Yu, {Hann Chin} and Ju, {Fong Yuan} and Tsai, {Chih Ping} and Chang, {Wen Hsun} and Hsu, {Yen Mei} and Lee, {Na Rong} and Chen, {Chih Yao} and Chang, {Ting Chen} and Chang, {Wen Chun} and Chen, {Chii Hou} and Chen, {Ruey Jian} and Chow, {Song Nan} and Lien, {Yih Ron} and Sheu, {Bor Ching} and Torng, {Pao Ling} and Yen, {Men Luh} and Lee, {Wen Ling} and Wang, {Kuan Chin} and Chang, {Chih Long} and Chen, {Chih Ping} and Chen, {Jen Ruei} and Chen, {Tze Chien} and Huang, {Jian Pei} and Huang, {Ming Chao} and Wang, {Yeou Lih} and Chang, {Cheng Chang} and Liu, {Jah Yao} and Su, {Her Young} and Wang, {Yu Chi} and Yu, {Mu Hsien} and Huang, {Lee Wen} and Seow, {Kok Min} and Lai, {Tsung Hsuan} and Lee, {Fa Kung} and Chen, {Ching Hui} and Huang, {Ben Shian} and Hsiao, {Sheng Mou} and Sun, {Hsu Dong} and Wu, {Wen Yih} and Teng, {Sen Wen} and Chen, {Kuo Hu} and Hung, {Jeng Hsiu} and Lai, {Hung Cheng} and Yuan, {Chiou Chung} and Hsieh, {Ching Hung} and Wang, {Chin Jung} and Chang, {Shing Jyh} and Hung, {Man Jung} and Hsu, {Shih Tien} and Ke, {Yu Min} and Lu, {Chien Hsing} and Lou Sun and Chang, {Wei Chun} and Hung, {Yao Ching} and Lin, {Wu Chou} and Wang, {Po Hui} and Chen, {Tze Ho} and Li, {Yiu Tai} and Wu, {Meng Hsing} and Huang, {Kuo Feng} and Fu, {Hung Chun} and Chen, {San Nung} and Chiang, {An Jen} and Li, {Ju Yueh} and Lin, {Li Te} and Tsai, {Hsiao Wen} and Tsui, {Kuan Hao}",

note = "Publisher Copyright: {\textcopyright} 2016",

year = "2016",

month = aug,

day = "1",

doi = "10.1016/j.tjog.2016.04.034",

language = "English",

volume = "55",

pages = "472--479",

journal = "Taiwanese Journal of Obstetrics and Gynecology",

issn = "1028-4559",

publisher = "Elsevier Taiwan LLC",

number = "4",

}

Horng, HC, Wen, KC, Wang, PH, Chen, YJ, Yen, MS, Ng, HT, Chang, YH, Chang, Y, Chao, HT, Chao, KC, Chuang, CM, Ho, CH, Huang, CY, Hung, ZC, Jiang, LY, Lau, HY, Li, HY, Lin, CY, Liu, CH, Sun, PL, Twu, NF, Wu, HH, Yu, HC, Ju, FY, Tsai, CP, Chang, WH, Hsu, YM, Lee, NR, Chen, CY, Chang, TC, Chang, WC, Chen, CH, Chen, RJ, Chow, SN, Lien, YR, Sheu, BC, Torng, PL, Yen, ML, Lee, WL, Wang, KC, Chang, CL, Chen, CP, Chen, JR, Chen, TC, Huang, JP, Huang, MC, Wang, YL, Chang, CC, Liu, JY, Su, HY, Wang, YC, Yu, MH, Huang, LW, Seow, KM, Lai, TH, Lee, FK, Chen, CH, Huang, BS, Hsiao, SM, Sun, HD, Wu, WY, Teng, SW, Chen, KH, Hung, JH, Lai, HC, Yuan, CC, Hsieh, CH, Wang, CJ, Chang, SJ, Hung, MJ, Hsu, ST, Ke, YM, Lu, CH, Sun, L, Chang, WC, Hung, YC, Lin, WC, Wang, PH, Chen, TH, Li, YT, Wu, MH, Huang, KF, Fu, HC, Chen, SN, Chiang, AJ, Li, JY, Lin, LT, Tsai, HW & Tsui, KH 2016, 'Uterine sarcoma Part II—Uterine endometrial stromal sarcoma: The TAG systematic review', Taiwanese Journal of Obstetrics and Gynecology, 卷 55, 編號 4, 頁 472-479. https://doi.org/10.1016/j.tjog.2016.04.034

TY - JOUR

T1 - Uterine sarcoma Part II—Uterine endometrial stromal sarcoma

T2 - The TAG systematic review

AU - Horng, Huann Cheng

AU - Wen, Kuo Chang

AU - Wang, Peng Hui

AU - Chen, Yi Jen

AU - Yen, Ming Shyen

AU - Ng, Heung Tat

AU - Chang, Yen Hou

AU - Chang, Yi

AU - Chao, Hsiang Tai

AU - Chao, Kuan Chong

AU - Chuang, Chi Mu

AU - Ho, Chi Hong

AU - Huang, Chen Yu

AU - Hung, Zhi Chen

AU - Jiang, Ling Yu

AU - Lau, Hei Yu

AU - Li, Hsin Yang

AU - Lin, Chi Yao

AU - Liu, Chia Hao

AU - Sun, Pi Lin

AU - Twu, Nae Fang

AU - Wu, Hua Hsi

AU - Yu, Hann Chin

AU - Ju, Fong Yuan

AU - Tsai, Chih Ping

AU - Chang, Wen Hsun

AU - Hsu, Yen Mei

AU - Lee, Na Rong

AU - Chen, Chih Yao

AU - Chang, Ting Chen

AU - Chang, Wen Chun

AU - Chen, Chii Hou

AU - Chen, Ruey Jian

AU - Chow, Song Nan

AU - Lien, Yih Ron

AU - Sheu, Bor Ching

AU - Torng, Pao Ling

AU - Yen, Men Luh

AU - Lee, Wen Ling

AU - Wang, Kuan Chin

AU - Chang, Chih Long

AU - Chen, Chih Ping

AU - Chen, Jen Ruei

AU - Chen, Tze Chien

AU - Huang, Jian Pei

AU - Huang, Ming Chao

AU - Wang, Yeou Lih

AU - Chang, Cheng Chang

AU - Liu, Jah Yao

AU - Su, Her Young

AU - Wang, Yu Chi

AU - Yu, Mu Hsien

AU - Huang, Lee Wen

AU - Seow, Kok Min

AU - Lai, Tsung Hsuan

AU - Lee, Fa Kung

AU - Chen, Ching Hui

AU - Huang, Ben Shian

AU - Hsiao, Sheng Mou

AU - Sun, Hsu Dong

AU - Wu, Wen Yih

AU - Teng, Sen Wen

AU - Chen, Kuo Hu

AU - Hung, Jeng Hsiu

AU - Lai, Hung Cheng

AU - Yuan, Chiou Chung

AU - Hsieh, Ching Hung

AU - Wang, Chin Jung

AU - Chang, Shing Jyh

AU - Hung, Man Jung

AU - Hsu, Shih Tien

AU - Ke, Yu Min

AU - Lu, Chien Hsing

AU - Sun, Lou

AU - Chang, Wei Chun

AU - Hung, Yao Ching

AU - Lin, Wu Chou

AU - Wang, Po Hui

AU - Chen, Tze Ho

AU - Li, Yiu Tai

AU - Wu, Meng Hsing

AU - Huang, Kuo Feng

AU - Fu, Hung Chun

AU - Chen, San Nung

AU - Chiang, An Jen

AU - Li, Ju Yueh

AU - Lin, Li Te

AU - Tsai, Hsiao Wen

AU - Tsui, Kuan Hao

PY - 2016/8/1

Y1 - 2016/8/1

N2 - Endometrial stromal tumors are rare uterine tumors (<1%). Four main categories include endometrial stromal nodule, low-grade endometrial stromal sarcoma (LG-ESS), high-grade endometrial stromal sarcoma (HG-ESS), and uterine undifferentiated sarcoma (UUS). This review is a series of articles discussing the uterine sarcomas. LG-ESS, a hormone-dependent tumor harboring chromosomal rearrangement, is an indolent tumor with a favorable prognosis, but characterized by late recurrences even in patients with Stage I disease, suggesting the requirement of a long-term follow-up. Patients with HG-ESS, based on the identification of YWHAE-NUTM2A/B (YWHAE-FAM22A/B) gene fusion, typically present with advanced stage diseases and frequently have recurrences, usually within a few years after initial surgery. UUS is, a high-grade sarcoma, extremely rare, lacking a specific line of differentiation, which is a diagnosis of exclusion (the wastebasket category, which fails to fulfill the morphological and immunohistochemical criteria of translocation-positive ESS). Surgery is the main strategy in the management of uterine sarcoma. Due to rarity, complex biological characteristics, and unknown etiology and risk factors of uterine sarcomas, the role of adjuvant therapy is not clear. Only LG-ESS might respond to progestins or aromatase inhibitors.

AB - Endometrial stromal tumors are rare uterine tumors (<1%). Four main categories include endometrial stromal nodule, low-grade endometrial stromal sarcoma (LG-ESS), high-grade endometrial stromal sarcoma (HG-ESS), and uterine undifferentiated sarcoma (UUS). This review is a series of articles discussing the uterine sarcomas. LG-ESS, a hormone-dependent tumor harboring chromosomal rearrangement, is an indolent tumor with a favorable prognosis, but characterized by late recurrences even in patients with Stage I disease, suggesting the requirement of a long-term follow-up. Patients with HG-ESS, based on the identification of YWHAE-NUTM2A/B (YWHAE-FAM22A/B) gene fusion, typically present with advanced stage diseases and frequently have recurrences, usually within a few years after initial surgery. UUS is, a high-grade sarcoma, extremely rare, lacking a specific line of differentiation, which is a diagnosis of exclusion (the wastebasket category, which fails to fulfill the morphological and immunohistochemical criteria of translocation-positive ESS). Surgery is the main strategy in the management of uterine sarcoma. Due to rarity, complex biological characteristics, and unknown etiology and risk factors of uterine sarcomas, the role of adjuvant therapy is not clear. Only LG-ESS might respond to progestins or aromatase inhibitors.

KW - diagnosis

KW - endometrial stromal sarcoma

KW - treatment

KW - undifferentiated sarcoma

KW - uterine sarcoma

KW - uterus

UR - http://www.scopus.com/inward/record.url?scp=84990838685&partnerID=8YFLogxK

U2 - 10.1016/j.tjog.2016.04.034

DO - 10.1016/j.tjog.2016.04.034

M3 - Review article

C2 - 27590366

AN - SCOPUS:84990838685

SN - 1028-4559

VL - 55

SP - 472

EP - 479

JO - Taiwanese Journal of Obstetrics and Gynecology

JF - Taiwanese Journal of Obstetrics and Gynecology

IS - 4

ER -

Uterine sarcoma Part II—Uterine endometrial stromal sarcoma: The TAG systematic review

摘要

存取文件

其它文件與鏈接

指紋

引用此